Michael Cherny
Stock Analyst at Leerink Partners
(3.82)
# 680
Out of 4,980 analysts
116
Total ratings
52.27%
Success rate
9.25%
Average return
Main Sectors:
Stocks Rated by Michael Cherny
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PINC Premier | Maintains: Underperform | $19 → $21 | $26.81 | -21.67% | 10 | Aug 19, 2025 | |
| CAH Cardinal Health | Maintains: Outperform | $188 → $186 | $152.47 | +21.99% | 13 | Aug 12, 2025 | |
| PGNY Progyny | Upgrades: Outperform | $28 | $23.17 | +20.85% | 11 | Jul 8, 2025 | |
| BOLD Boundless Bio | Downgrades: Market Perform | $15 → $3 | $1.16 | +158.62% | 2 | May 28, 2025 | |
| MCK McKesson | Maintains: Buy | $755 → $800 | $719.80 | +11.14% | 13 | May 9, 2025 | |
| NVST Envista Holdings | Maintains: Buy | $26 → $23 | $21.61 | +6.43% | 11 | Apr 29, 2025 | |
| MEDP Medpace Holdings | Initiates: Market Perform | $330 | $497.59 | -33.68% | 1 | Mar 24, 2025 | |
| HIMS Hims & Hers Health | Maintains: Market Perform | $24 → $40 | $51.76 | -22.72% | 10 | Feb 25, 2025 | |
| CVS CVS Health | Upgrades: Outperform | $55 → $75 | $74.67 | +0.44% | 11 | Feb 13, 2025 | |
| DOCS Doximity | Upgrades: Outperform | $60 → $90 | $70.26 | +28.10% | 2 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $235 → $280 | $135.91 | +106.02% | 2 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $135 → $174 | $183.46 | -5.16% | 2 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $69 → $84 | $69.52 | +20.83% | 2 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $260 → $248 | $190.69 | +30.05% | 2 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $270 → $255 | $175.11 | +45.62% | 3 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $13.93 | - | 8 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $277 → $275 | $302.80 | -9.18% | 3 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $260 | $279.72 | -7.05% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $8 | $4.22 | +89.57% | 5 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $19 | $10.92 | +73.99% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $17 | $7.77 | +118.79% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $113 → $53 | $4.88 | +975.82% | 2 | Jan 5, 2022 |
Premier
Aug 19, 2025
Maintains: Underperform
Price Target: $19 → $21
Current: $26.81
Upside: -21.67%
Cardinal Health
Aug 12, 2025
Maintains: Outperform
Price Target: $188 → $186
Current: $152.47
Upside: +21.99%
Progyny
Jul 8, 2025
Upgrades: Outperform
Price Target: $28
Current: $23.17
Upside: +20.85%
Boundless Bio
May 28, 2025
Downgrades: Market Perform
Price Target: $15 → $3
Current: $1.16
Upside: +158.62%
McKesson
May 9, 2025
Maintains: Buy
Price Target: $755 → $800
Current: $719.80
Upside: +11.14%
Envista Holdings
Apr 29, 2025
Maintains: Buy
Price Target: $26 → $23
Current: $21.61
Upside: +6.43%
Medpace Holdings
Mar 24, 2025
Initiates: Market Perform
Price Target: $330
Current: $497.59
Upside: -33.68%
Hims & Hers Health
Feb 25, 2025
Maintains: Market Perform
Price Target: $24 → $40
Current: $51.76
Upside: -22.72%
CVS Health
Feb 13, 2025
Upgrades: Outperform
Price Target: $55 → $75
Current: $74.67
Upside: +0.44%
Doximity
Feb 7, 2025
Upgrades: Outperform
Price Target: $60 → $90
Current: $70.26
Upside: +28.10%
Jan 6, 2025
Upgrades: Outperform
Price Target: $235 → $280
Current: $135.91
Upside: +106.02%
Jan 6, 2025
Upgrades: Outperform
Price Target: $135 → $174
Current: $183.46
Upside: -5.16%
Jan 6, 2025
Upgrades: Buy
Price Target: $69 → $84
Current: $69.52
Upside: +20.83%
Nov 19, 2024
Reiterates: Outperform
Price Target: $260 → $248
Current: $190.69
Upside: +30.05%
Nov 19, 2024
Reiterates: Outperform
Price Target: $270 → $255
Current: $175.11
Upside: +45.62%
Nov 7, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $13.93
Upside: -
Oct 7, 2024
Maintains: Outperform
Price Target: $277 → $275
Current: $302.80
Upside: -9.18%
Feb 26, 2024
Initiates: Outperform
Price Target: $260
Current: $279.72
Upside: -7.05%
Feb 26, 2024
Initiates: Outperform
Price Target: $8
Current: $4.22
Upside: +89.57%
Feb 26, 2024
Initiates: Market Perform
Price Target: $19
Current: $10.92
Upside: +73.99%
Feb 26, 2024
Initiates: Market Perform
Price Target: $17
Current: $7.77
Upside: +118.79%
Jan 5, 2022
Downgrades: Underperform
Price Target: $113 → $53
Current: $4.88
Upside: +975.82%